Table 2.
Demographic, clinical and neuropathologic characteristics of postmortem brain donors
| Controls | PD | Group-wise comparison | |||
|---|---|---|---|---|---|
| H1/H1 | H2/H2 | H1/H1 | H2/H2 | P value | |
| (n = 7) | (n = 5) | (n = 9) | (n = 5) | ||
| Sex (female) [n (%)] | 4 (57.1) | 4 (80.0) | 4 (44.4) | 3 (60.0) | 0.380† |
| Age at death (y) [mean (SD)] | 74.0 (6.8) | 81.0 (15.2) | 74.2 (3.2) | 77.6 (7.2) | 0.433# |
| PMI (h) [mean (SD)] | 15.7 (7.5) | 25.3 (9.2) | 15.9 (5.9) | 15.7 (9.1) | 0.145# |
| Age at diagnosis (y) [mean (SD)] | – | – | 64.3 (6.5) | 68.0 (7.8) | 0.415‡ |
| Disease duration (y) [mean (SD)] | – | – | 9.0 (7.4) | 10.25 (3.4) | 0.760‡ |
| Lewy inclusion pathology in ctx-fg | 0.536* | ||||
| None [n (%)] | – | – | 1 (11.1 | 1 (20.0) | |
| Few [n (%)] | – | – | 4 (44.4) | 3 (60.0) | |
| Moderate [n (%)] | – | – | 3 (33.3) | – | |
| Many [n (%)] | – | – | 1 (11.1) | 1 (20.0) | |
| LBD Braak stage | 0.504* | ||||
| 1 [n (%)] | – | – | – | – | |
| 2 [n (%)] | – | – | – | – | |
| 3 [n (%)] | – | – | – | – | |
| 4 [n (%)] | – | – | 1 (11.1) | 1 (16.7) | 7 |
| 5 [n (%)] | – | – | 2 (22.2) | – | |
| 6 [n (%)] | – | – | 6 (66.7) | 4 (83.3) | |
| LBD McKeith stage | 0.472* | ||||
| Neocortical [n (%)] | – | – | 5 (55.6) | 4 (80.0) | |
| Limbic [n (%)] | – | – | 2 (22.2) | – | |
| Brain stem predominant [n (%)] | – | – | 1 (11.1) | 1 (20.0) | |
| AD Braak and Braak stage | 0.363* | ||||
| I [n (%)] | 3 (42.9) | 3 (75.0) | 4 (44.4) | 4 (80.0) | |
| II [n (%)] | 4 (57.1) | – | 4 (44.4) | 1 (20.0) | |
| III [n (%)] | – | 1 (25.0) | 1 (11.1) | – | |
| IV [n (%)] | – | – | – | – | |
| V [n (%)] | – | – | – | – | |
| VI [n (%)] | – | – | – | – | |
| CERAD score | 0.280* | ||||
| 0 [n (%)] | 7 (100.0) | 5 (100.0) | 8 (88.9) | 3 (60.0) | |
| A [n (%)] | – | – | – | 2 (40.0) | |
| B [n (%)] | – | – | 1 (11.1) | – | |
| C [n (%)] | – | – | – | – | |
The LBD Braak stage and AD Braak and Braak stage consist of six stages, each. The CERAD score describes neuritic Amyloid-ß plaques in levels of 0, A, B, C. Lewy inclusion pathology assessed semi-quantitatively the burden of Lewy neurites and Lewy bodies in the target brain region cortex of fusiform gyrus. For group-wise comparisons of the subgroups, defined by MAPT haplotype and disease status, P values were calculated by: *, Chi-squared test; #, one-way ANOVA; ‡, unpaired Student’s t-test; †, Fisher’s exact test
AD, Alzheimer’s disease; CERAD, The Consortium to Establish a Registry for Alzheimer's Disease; ctx-fg, cortex of fusiform gyrus; LBD, Lewy body disease; PD, Parkinson’s disease; PMI, postmortem interval